|Bid||1.42 x 8000|
|Ask||1.54 x 300|
|Day's Range||1.46 - 1.52|
|52 Week Range||1.32 - 3.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.10|
SAN DIEGO, Feb. 20, 2018-- Vical Incorporated announced today the initiation of a Phase 2 trial of the Company’ s VL-2397 novel antifungal compound. The multicenter, open label randomized clinical study, ...
SAN DIEGO, Feb. 01, 2018-- Vical Incorporated and the Mycoses Study Group Education and Research Consortium today announced the establishment of a collaboration to advance Vical’ s novel antifungal drug ...
SAN DIEGO, Jan. 30, 2018-- Vical Incorporated today announced a restructuring to conserve capital and to focus its efforts on VL-2397, its antifungal drug product candidate which is entering a pivotal ...
WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections.
TOKYO and SAN DIEGO, Jan. 22, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Vical Incorporated (VICL) announced today that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant (HSCT) recipients, did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. "We are disappointed that the results did not demonstrate a significant improvement in overall survival and reduction in CMV end-organ disease," said Bernhardt G. Zeiher, president of Development, Astellas.
TOKYO and SAN DIEGO, Jan. 22, 2018--. Astellas Pharma Inc. and Vical Incorporated announced today that ASP0113, an investigational DNA vaccine being developed for cytomegalovirus- seropositive hematopoietic ...
NEW YORK, Jan. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US ...
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Vical Incorporated (NASDAQ:VICL), as the company does not have to adhere to strict debt covenants. However, it also faces higherRead More...
When Vical Incorporated (NASDAQ:VICL) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happening inRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
The San Diego-based company said it had a loss of 27 cents per share. The drug developer posted revenue of $3.2 million in the period. The company's shares closed at $2.38. A year ago, they were trading ...
Categories: Yahoo FinanceGet free summary analysis Vical, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Vical, Inc. – CytRx Corporation, Newlink Genetics Corporation, Agenus Inc., Chimerix, Inc., Celldex Therapeutics, Inc., Sanofi Sponsored ADR, Pfizer Inc., Merck & Co., Inc. and Bristol-Myers Squibb Company (CYTR-US, ... Read more (Read more...)